Reaching out to the lost generation of adults with early-treated phenylketonuria (PKU)

Molecular Genetics and Metabolism

Volumn 101, Issue 2-3, 2010, Pages 146-148

  Burton, Barbara K ^a,b   Leviton, Lauren ^a  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adults; Outcome; Phenylketonuria; Treatment

Indexed keywords

PHENYLALANINE;

ADULT; ARTICLE; BLOOD LEVEL; BRAIN FUNCTION; COGNITIVE DEFECT; CONTROLLED STUDY; EDUCATION PROGRAM; EMOTIONALITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHENYLKETONURIA; PRIORITY JOURNAL; SOCIAL INTERACTION;

ADULT; BIOPTERIN; EDUCATIONAL STATUS; HUMANS; MENTAL DISORDERS; PATIENT COMPLIANCE; PHENYLALANINE; PHENYLKETONURIAS;

EID: 77957242255     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2010.06.006     Document Type: Article

References (21)

1. Walter J.H., White F.J., Hall S.K., MacDonald A., Rylance G., Boneh A., Francis D.E., Shortland G.J., Schmidt M., Vail A. How practical are recommendations for dietary control in phenylketonuria?. Lancet 2002, 360:55-57.
2. Christ S.E., Huijbregts S.C.J., de Sonneville L.M.J., White D.A. Executive function in early-treated phenylketonuria: profile and underlying mechanisms. Mol. Genet. Metab. 2010, 99:S22-S32.
3. Moyle J.J., Fox A.M., Arthur M., Bynevelt M., Burnett J.R. Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU. Neuropsychol. Rev. 2007, 17:91-101.
4. Pietz J., Dunckelmann R., Rupp A., Rating D., Meinck H.M., Schmidt H., Bremer H.J. Neurological outcome in adult patients with early-treated phenylketonuria. Eur. J. Pediatr. 1998, 157:824-830.
5. Perez-Duenas B., Valls-Sole J., Fernandez-Alvarez E., Conell J., Vilaseca M.A., Artuch R., Campisol J. Characterization of tremor in phenylketonuric patients. J. Neurol. 2005, 25:1328-1334.
6. McCombe P.A., McLaughlin D.B., Chalk J.B., Brown N.N., McGill J.J., Pender M.P. Spasticity and white matter abnormalities in adult phenylketonuria. J. Neurol. Neurosurg. Psychiatry 1992, 55:359-361.
7. Anderson P.J., Wood S.J., Francis D.E., Coleman L., Anderson V., Boneh A. Are neuropsychological impairments in children with early-treated phenylketonuria (PKU) related to white matter abnormalities or elevated phenylalanine levels?. Dev. Neuropsychol. 2007, 32:645-668.
8. Koch R., Azan C., Friedman E.G., Williamson M.L. Paired comparisons between early treated PKU children and their matched sibling controls on intelligence and school achievement test results at eight years of age. J. Inherit. Metab. Dis. 1984, 7:86-90.
9. Waisbren S.E., Noel K., Fahrbach K., Cella C., Frame D., Dorenbaum A., Levy H. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol. Genet. Metab. 2007, 92:63-70.
10. Brumm V.L., Bilder D., Waisbren S.E. Psychiatric symptoms and disorders in phenylketonuria. Mol. Genet. Metab. 2010, 99:S59-S63.
11. Koch R., Burton B.K., Hoganson G., Peterson R., Rhead W., Rouse B., Scott R., Wolff J., Stern A.M., Guttler F., Nelson M., de la Cruz F., Coldwell J., Erbe R., Geraghty M.T., Shear C., Thomas J., Azen C. Phenylketonuria in adulthood: a collaborative study. J. Inherit. Metab. Dis. 2002, 25:333-346.
12. Rouse B., Azen C., Koch R., Matalon R., Hanley W., de la Cruz F., Trefz F., Friedman E., Shifrin H. Maternal Phenylketonuria Collaborative Study (MPKUCS) offspring: facial anomalies, malformations, and early neurologic sequelae. Am. J. Med. Genet. 1997, 69:89-95.
13. Clarke J.T. The Maternal Phenylketonuria Project: a summary of progress and challenges for the future. Pediatrics 2003, 112:1584-1587.
14. Levy H.L., Milanowski A., Chakrapani A., Cleary M., Lee P., Trefz F.K., Whitley C.B., Feillet F., Feigenbaum A.S., Bebchuk J.D., Christ-Schmidt H., Dorenbaum A. Lancet 2007, 370:504-510.
15. Trefz F.K., Burton B.K., Longo N., Casanova M.M., Gruskin D.J., Dorenbaum A., Kakkis E.D., Crombez E.A., Grange D.K., Harmatz P., Lipson M.H., Milanowski A., Randolph L.M., Vockley J., Whitley C.B., Wolff J.A., Bebchuk J., Christ-Schmidt H., Hennermann J.B. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized double-blind, placebo-controlled study. J. Pediatr. 2009, 154:700-707.
16. Sarkissian C.N., Gamez A., Wang L., Charbonneau M., Fitzpatrick P., Lemontt J.F., Zhao B., Vellard M., Bell S.M., Henschell C., Lambert A., Tsuruda L., Stevens R.C., Scriver C.R. Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:20894-20899.
17. Harding C. Progress toward cell-directed therapy for phenylketonuria. Clin. Genet. 2008, 74:97-104.
18. Bik-Multanowski M., Didycz B., Mozrzymas R., Nowacka M., Kaluzny L., Cichy W., Schneiberg B., Amilkiewicz J., Bilar A., Gizewska M., Lange A., Starostecka E., Chrobot A., Wojcicka-Bartlomiejczyk B.I., Milanowski A. Quality of life in noncompliant adults with phenylketonuria after resumption of the diet. J. Inherit. Metab. Dis. 2008, 265:30-633. [Electronic publication ahead of print].
19. Cleary M.A., Walter J.H., Wraith J.E., White F., Tyler K., Jenkins P.R. Magnetic resonance imaging in phenylketonuria: reversal of cerebral white matter change. J. Pediatr. 1995, 127:251-255.
20. Simon E., Schwarz M., Roos J., Dragano N., Geraedts M., Siegrist J., Kamp G., Wendel U. Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU). Health Qual. Life Outcomes 2008, 6:25.
21. Gentile J.K., Ten Hoedt A.E., Bosch A.M. Psychosocial aspects of PKU: hidden disabilities-a review. Mol. Genet. Metab. 2010, S64-S67.